Celgene Corp. (CELG)

100.95
0.56 0.56
NASDAQ : Health Technology
Prev Close 100.39
Open 100.50
Day Low/High 100.40 / 101.19
52 Wk Low/High 58.59 / 100.96
Volume 2.64M
Avg Volume 3.61M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 71.28B
EPS 5.70
P/E Ratio 13.78
Div & Yield N.A. (N.A)
Cramer: Trend Appears to Be 'If It's Up, Buy It'

Cramer: Trend Appears to Be 'If It's Up, Buy It'

Where is this coming from?

Celgene New Top Pick at RBC

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I've Prepared for Hurricane Irma -- and a Market Pullback

As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.

How I'm Prepared for Irma -- and a Pullback

How I'm Prepared for Irma -- and a Pullback

As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

This team is playoff-ready and built for the ages.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

My Takeaways and Observations

"Yeah, well, that's just, like, your opinion, man." -- The Dude, The Big Lebowski Strikes and gutters today -- in a market characterized by winners and losers and weakening breadth. Ups and downs.    Amazon's shares may be signaling there is no fun,...

Cramer: Random Movement Is Exactly That

Cramer: Random Movement Is Exactly That

Nothing's happening, but that doesn't mean you have to make something happen.

Be Cautious in Case of a Second-Half Hiccup

Be Cautious in Case of a Second-Half Hiccup

The market seems fully valued, so I'm building up cash as we head into historically volatile months.

Back to Basics in Biotech

Back to Basics in Biotech

Stop losses do not work in this part of the market.

Back to Basics in Biotech

Back to Basics in Biotech

Stop losses do not work in this part of the market.

Looking to Buy Some Celgene? Now's a Good Time

Looking to Buy Some Celgene? Now's a Good Time

CELG looks like it has a promising future, according to the charts.

My Takeaways and Observations (Early Edition)

The story's in the past with nothin' to recall, I've got my life to live and I don't need you at all. The roller-coaster ride we took is nearly at an end, I bought my ticket with my tears, that's all I'm gonna spend. -- The Cyrkle, Red Rubber Ball M...

Here's Why I'm Valuing Value Over Growth

Here's Why I'm Valuing Value Over Growth

Multiples have become quite rich and dysfunction in Washington could end up biting the markets.

Biotech Bucking the Trend

Coming up on the two-hour mark on trading. The market is down slightly down across the board, with Nasdaq being affected by disappointing results from Starbucks and Amazon . The failure to even getting a "skinny" repeal and replacement of the Afford...

Now Up to the Plate, Today's Pinch Hitter, Bret Jensen!

It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...

Here's What Up (and Down)

After 90 minutes of trading here are some market features:   * Bonds are getting schmeissed. The 10-year U.S. note yield is close to 2.32% and the long bond is knocking on the door of 3.00%. A possible equity market headwind. * Retail still has a ni...

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.

My Takeaways and Observations (Afternoon Edition)

"If it is what you say I love it...." - Donald Trump Jr Risk Happens Fast -- and the reverberations of today's disclosures may weigh on the markets for a while as the Administration's initiatives get further lost in the bowels of Washington DC.   Th...

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

My Takeaways and Observations

"I'd unravel every riddle for any individ'le, In trouble or in pain. With the thoughts I'd be thinkin' I could be another Lincoln If I only had a brain." -- "If I Only Had A Brain" (Harold Arlen and E.Y. Harburg), from "The Wizard of Oz" I believe I...

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

The Market Advance Narrows

"For a day where the S&P was essentially flat, there was a lot going on beneath the surface. Just a few days ago, everyone was so excited about the rally, but I pointed out that the cumulative advance/decline line (breadth) had not made a higher hig...

Cramer: This Is No Country for Old Value

Cramer: This Is No Country for Old Value

Down-and-out stocks have become toxic.

Celgene Bucks Biotech Trend

Stocks wrapped up a directionless day of trading near even. Despite the turmoil in D.C., volatility in the market remains remarkably low. Celgene bucked the slightly downward trend in biotech as Leerink Swann reiterated its Buy rating. Oppenheimer d...